Autolus Therapeutics (AUTL) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$220.7 million.

  • Autolus Therapeutics' Net Income towards Common Stockholders rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • As of FY2024, Autolus Therapeutics' Net Income towards Common Stockholders stood at -$220.7 million, which was down 5.89% from -$208.4 million recorded in FY2023.
  • Autolus Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$142.1 million during FY2021, with a 5-year trough of -$220.7 million in FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$208.4 million (2023), whereas its average is -$192.6 million.
  • In the last 5 years, Autolus Therapeutics' Net Income towards Common Stockholders grew by 24.91% in 2021 and then crashed by 39.98% in 2023.
  • Autolus Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$189.3 million in 2020, then increased by 24.91% to -$142.1 million in 2021, then decreased by 4.73% to -$148.9 million in 2022, then plummeted by 39.98% to -$208.4 million in 2023, then decreased by 5.89% to -$220.7 million in 2024.